Journal
JOURNAL OF ADOLESCENT HEALTH
Volume 50, Issue 2, Pages 110-131Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jadohealth.2011.10.010
Keywords
-
Funding
- National Institutes of Health
- Office of the Director
- Fogarty International Center
- Office of AIDS Research
- National Cancer Centre
- National Eye Institute
- National Heart, Blood and Lung Institute
- National Institute of Dental and Craniofacial Research
- National Institute on Drug Abuse
- National Institute of Mental Health
- National Institute of Allergy and Infectious Diseases Health
- NIH Office of Women's Health and Research through Vanderbilt University [R24 TW007988]
- American Relief and Recovery Act
- GlaxoSmithKline BioLogicals
Ask authors/readers for more resources
Purpose: Global data on human papillomavirus (HPV) serological and deoxyribonucleic acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies. Methods: We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV-16, -18, -6, and -11. Results: One hundred seventeen studies were included; participants' ages ranged from several hours to >90 years. HPV-16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than among men, and peaked around ages 25-40 years. HPV-18 seroprevalence was generally lower than HPV-16 with a later age peak. Data were limited for HPV-6 and -11, both of which peaked at ages similar to HPV-18. Among 9-26-year-old females, HPV-16 seroprevalence ranged from 0%-31% in North America, 21%-30% in Africa, 0%-23% in Asia/Australia, 0%-33% in Europe, and 13%-43% in Central and South America. HPV-16/-18 DNA prevalence peaked 10-15 years before corresponding HPV-16/-18 antibody prevalence. Conclusions: Females within the HPV vaccine-eligible age-group (9-26 years) had a range of dual HPV-16 DNA and serology negativity from 81%-87%, whereas 90%-98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination. (C) 2012 Society for Adolescent Health and Medicine. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available